COVID-19 Vaccine Clinical Trials-Study-Pfizer-90% efficiency
First, it was a rumor, then a confirmed virus, then an imported one, then a pandemic, then a killer pandemic. Then people started their own research and clinical protocols. This was the first time, medical professionals were learning about a virus alongside the common man. Thanks to the internet, RNA, DNA was common lingo, and different protocols, fatality rates, comorbidities were discussed in bylanes of Chennai and Mumbai. Masks have become common, efficacy of the masks is another thing. What would you argue with a person selling flowers at a road junction for 5rs about the efficiency of a 300rs worth N95 mask? She is wearing a cloth mask, and that is a good deterrent.
Every drug manufacturer could get lifetime bragging rights, speed tracking the drug discovery process, and potential profits. Russia and China have their own vaccine and they have broadcast to the world, that they have already tested their drugs on their population and it is doing extremely well. Due to advocacy efforts, all leading vaccine players have released their clinical trial papers-the the first time they did so. It is an industry secret, but since this is pandemic times, and the vaccine is being fast-tracked, people and the government want to be doubly sure of the side effects of the potential vaccine.
This is the first time, a product with a global consumer base equivalent to the world population and immediate sales.
- Out of the 2 vaccine candidates used, one has been proved effective at 90%
- 90% is achieved at 7 days after the second dose, implying patients are likely to become covid immune after 28 days
- About 43,000 people have participated in this clinical trial, out of these, 38,000 people have been given the second dose
- 30% of participants in this study are from different racial and ethnic backgrounds
- It is an RNA based vaccine
- This vaccine encoding a viral antigen, which is then expressed by the vaccine recipient as a protein capable of eliciting protective immune responses
- These are not a live-attenuated vaccine approach, which has the possibility of live infection and take more time for vaccine development
- 1 or 2 doses is prepared, in general, any new vaccine starts with more dosage to improve the efficacy
- 7 days, 1 month, and 6 months after-effects is validated after the vaccine injection
- Healthy adults, participants without evidence of infection, confirmed COVID-19, confirmed severe patients are included in these trials
- It is a multicenter, multinational, randomized, placebo-controlled study, implying it is fool-proof and includes a diversity of patients
- Age groups of 18–55, 65–85, and ≥ 16 years of age has been covered in these trials
- Like all clinical trials, the majority of them will receive the injection, and the minority participants receiving the placebo
- Participants are furnished, low-medium, and high dosage, consent is sought, blood samples, all body vitals pre-screened, and checked regularly in periods of time2
- Placebo is a saline injection, and others administered the actual two vaccine candidates
- Like all trials, there would be blinded clinical staff to perform this study in a risk-free fashion
- All systemic events like headache, fever, diarrhea, vomiting, are validated and sampled
- Detailed roadmaps of vaccine test days, monitoring days, with every event planned in detail for this study has been carried out by Pfizer
- The study is stopped in the event of more patients exhibiting severe symptoms
Reference:
https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf
